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Abstract
BACKGROUND—Prior studies with the use of a prospective–retrospective design including 
archival tumor samples have shown that gene-expression assays provide clinically useful 
prognostic information. However, a prospectively conducted study in a uniformly treated 
population provides the highest level of evidence supporting the clinical validity and usefulness of 
a biomarker.
METHODS—We performed a prospective trial involving women with hormone-receptor–
positive, human epidermal growth factor receptor type 2 (HER2)–negative, axillary node–negative 
breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0 cm in the 
greatest dimension and intermediate or high tumor grade) who met established guidelines for the 
consideration of adjuvant chemotherapy on the basis of clinicopathologic features. A reverse-
transcriptase–polymerase-chain-reaction assay of 21 genes was performed on the paraffin-
embedded tumor tissue, and the results were used to calculate a score indicating the risk of breast-
cancer recurrence; patients were assigned to receive endocrine therapy without chemotherapy if 
they had a recurrence score of 0 to 10, indicating a very low risk of recurrence (on a scale of 0 to 
100, with higher scores indicating a greater risk of recurrence).
RESULTS—Of the 10,253 eligible women enrolled, 1626 women (15.9%) who had a recurrence 
score of 0 to 10 were assigned to receive endocrine therapy alone without chemotherapy. At 5 
years, in this patient population, the rate of invasive disease–free survival was 93.8% (95% 
confidence interval [CI], 92.4 to 94.9), the rate of freedom from recurrence of breast cancer at a 
distant site was 99.3% (95% CI, 98.7 to 99.6), the rate of freedom from recurrence of breast cancer 
at a distant or local–regional site was 98.7% (95% CI, 97.9 to 99.2), and the rate of overall 
survival was 98.0% (95% CI, 97.1 to 98.6).
CONCLUSIONS—Among patients with hormone-receptor–positive, HER2-negative, axillary 
node–negative breast cancer who met established guidelines for the recommendation of adjuvant 
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chemotherapy on the basis of clinicopathologic features, those with tumors that had a favorable 
gene-expression profile had very low rates of recurrence at 5 years with endocrine therapy alone. 
(Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00310180.)
Breast cancer is the most common cancer in women worldwide and in the United States, and 
it is the leading cause of death from cancer in women worldwide.1 Prognostic factors for the 
recurrence of breast cancer at a distant site regardless of treatment include clinicopathologic 
features such as tumor size and grade and the number of axillary lymph nodes with 
metastasis.2 Predictive factors that identify a benefit from specific therapies include the 
expression of the estrogen receptor and the progesterone receptor, which identifies patients 
who benefit from adjuvant endocrine therapy,3 and overexpression of the human epidermal 
growth factor receptor 2 (HER2) protein (or HER2 gene amplification),4 which identifies 
patients who benefit from adjuvant HER2-directed therapy. Adjuvant chemotherapy reduces 
the risk of recurrence, even among patients with axillary node–negative disease who are at 
lower risk for recurrence.5–7
For contemporary taxane-based or anthracycline-based chemotherapy regimens, 
proportional reductions in risk have been shown to be affected only minimally by age, nodal 
status, tumor grade, estrogen-receptor expression, or use of adjuvant endocrine therapy.8 
These findings led a National Institutes of Health consensus panel in 2001 to conclude that 
“adjuvant polychemotherapy … should be recommended to the majority of women with 
localized breast cancer regardless of lymph node, menopausal, or hormone receptor status.”9 
The widespread use of adjuvant chemotherapy has contributed to the declining breast-cancer 
mortality that has been observed in the United States and other industrialized nations.10
More than 100,000 women in the United States received a diagnosis of estrogen-receptor–
positive breast cancer associated with negative axillary lymph nodes in 2014.11 Although 
approximately 85% of these women may be recurrence-free at 10 years with adjuvant 
endocrine therapy alone, the addition of chemotherapy leads to a relative reduction in the 
risk of recurrence of approximately 30% on average, which translates into an absolute 
benefit in the rate of freedom from recurrence of up to 5 percentage points.12,13 Many 
patients with estrogen-receptor– positive breast cancer would therefore be over-treated with 
chemotherapy on the basis of clinicopathologic features alone, since most would have been 
adequately treated with endocrine therapy alone.14
Previous studies have shown that a 21-gene expression assay provides additional prognostic 
information independent of clinicopathologic features15 and also predicts benefit from 
adjuvant chemotherapy in estrogen-receptor–positive disease.16,17 Prospective validation 
was performed with the use of archival tumor specimens from completed studies that used a 
prospective–retrospective design.18 However, validation in prospectively conducted studies 
provides the highest level of evidence supporting the clinical validity and ultimately the 
clinical usefulness of a new biomarker.19,20
Here we report the results of a prospectively conducted clinical trial, the Trial Assigning 
Individualized Options for Treatment (TAILORx). This trial was designed to further 
validate and refine the clinical usefulness of the 21-gene assay (Oncotype DX Recurrence 
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Score, Genomic Health) in a specified low-risk cohort of women with hormone-receptor–
positive, HER2-negative, axillary node–negative invasive breast cancer.
METHODS
Study Patients
The study included women 18 to 75 years of age with axillary node–negative invasive breast 
cancer that was estrogen-receptor–positive or progesterone-receptor–positive (or both) and 
that did not overexpress HER2. Patients had to meet National Comprehensive Cancer 
Network guidelines for the recommendation of adjuvant chemotherapy,21 including a 
primary tumor size of 1.1 to 5.0 cm in the greatest dimension for a tumor of any grade or a 
size of 0.6 to 1.0 cm in the greatest dimension for a tumor of intermediate or high histologic 
grade or nuclear grade (or both).
Other eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) 
performance- status score of 0 or 1 (on a scale from 0 to 5, with higher numbers indicating 
greater disability; a score of 0 indicates no symptoms, and a score of 1 mild symptoms) and 
normal hematologic, bone marrow, hepatic, renal, pulmonary, and cardiac function. Patients 
with HER2-overexpressing disease were excluded because most have a high risk of 
recurrence14 and because such patients benefit from adjuvant HER2-directed therapy plus 
chemotherapy.22
Study Protocol
This prospective clinical trial was sponsored by the National Cancer Institute (NCI), was 
coordinated by the ECOG and subsequently the ECOG–ACRIN Cancer Research Group, 
and included other participating NCI-sponsored groups. Patients were required to provide 
written informed consent, including willingness to have treatment assigned or randomly 
assigned on the basis of the genetic-assay results indicating the risk of recurrence.
All the patients had an Oncotype DX Recurrence Score, a reverse-transcriptase–
polymerasechain-reaction 21-gene assay performed on RNA extracted from formalin-fixed 
paraffin-embedded tissue, performed in a central laboratory (Genomic Health).15 The 
recurrence scores range from 0 to 100, with higher scores indicating a greater risk of 
recurrence. Patients with a score of 0 to 10 were assigned to receive endocrine therapy 
alone, and those with a score of 26 or higher were assigned to receive chemotherapy plus 
endocrine therapy. Prior studies indicated that patients with a score of less than 11 had a 
favorable prognosis with endocrine therapy alone15 and also that patients with a score of 26 
to 30 or higher derived substantially greater benefit from adjuvant chemotherapy.16,17 
Patients with a midrange score of 11 to 25 were randomly assigned to receive either 
chemotherapy plus endocrine therapy or endocrine therapy alone because the benefits of 
chemotherapy were uncertain in this group, yet the risk of recurrence was high enough to 
suggest that chemotherapy might be beneficial.
To minimize the potential for undertreatment of the participants enrolled in our trial, the 
recurrence-score ranges used in our study differed from those that were originally defined as 
low (≤10 in our study vs. <18 in the original definition), intermediate (11 to 25 vs. 18 to 30), 
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and high (≥26 vs. ≥31).14 The recurrence-score strata derived for the trial were based on 
prior studies that indicated that the risk of recurrence of breast cancer at a distant site at 10 
years after diagnosis and a 5-year course of tamoxifen could be as high as 10% among 
patients with a score of 11 (point estimate, 7%; 95% confidence interval [CI], 5 to 10) and 
up to 20% among those with a score of 25 (point estimate, 16%; 95% CI, 13 to 20),15 
indicating a risk that was substantial enough for a recommendation of adjuvant 
chemotherapy in patients with a score of 11 or higher.14
Study Oversight
The manuscript was written by the first author; the final version of the manuscript 
incorporated some changes recommended by the coauthors and Genomic Health. Data were 
collected by the Cancer Trials Support Unit and the ECOG–ACRIN Cancer Research Group 
Coordinating Center. All the authors vouch for the accuracy and completeness of the data 
and analyses presented and for the adherence of the study to the protocol, which is available 
with the full text of this article at NEJM.org. No commercial support was involved in the 
planning or execution of the study, although the genomic test used is commercially 
available.
Study End Points
The standardized definitions for efficacy end points (STEEP) criteria were used for the 
endpoint definitions.23 The primary trial end point was a time-to-event analysis of the rate of 
survival free from invasive cancer, with an invasive-cancer event defined as the first event 
of recurrence of ipsilateral breast tumor, local recurrence, regional recurrence, distant 
recurrence, contralateral second primary invasive cancer, second primary nonbreast invasive 
cancer (excluding nonmelanoma skin cancer), or death without evidence of recurrence 
(which corresponds to the STEEP definition of invasive disease–free survival).
Secondary end points included time-to-event analyses of the freedom from the recurrence of 
breast cancer at a distant site, with an event of breast cancer at a distant site defined as the 
first event of distant recurrence of breast cancer or death with distant recurrence, if death 
was the first manifestation of distant recurrence (which corresponds to the STEEP definition 
of distant recurrence–free interval); freedom from any recurrence, with recurrence defined 
as the first recurrence of breast cancer at any site (including ipsilateral breast cancer, local or 
regional recurrence, or distant recurrence) or death with recurrence, if death was the first 
manifestation of recurrence (which corresponds to the STEEP definition of recurrence-free 
interval); and the overall survival rate, which was defined as the proportion of patients who 
did not die (from any cause). End-point assessments that were consistent with standard of 
care at regular intervals were specified in the protocol, and copies of source documents 
supporting each event were reviewed and corroborated by one of the coauthors who did not 
have knowledge of the study group or the recurrence-score information.
Statistical Analysis
The overall sample size in all the risk strata defined according to recurrence score was 
driven by the need to include a sufficient number of patients with a score of 11 to 25 
(midrange risk) in order to test the noninferiority of endocrine therapy alone versus 
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chemotherapy plus endocrine therapy. At the fourth planned interim analysis held on March 
20, 2015, the ECOG–ACRIN data and safety monitoring committee recommended that the 
results of the low-risk group be released and that follow-up in the randomized midrange-risk 
stratum and the nonrandomized high-risk stratum continue as planned. Although there was 
no specific enrollment goal for the low-risk group, the large sample provided the 
opportunity to estimate 5-year event rates accurately.
Statistical comparisons of baseline characteristics were calculated with the use of the 
chisquare test for categorical variables and the Wilcoxon test and Student’s t-test for 
continuous variables. Tumor size in the greatest dimension, histologic grade of the tumor, 
and expression of estrogen receptor, progesterone receptor, and HER2 were determined 
locally and reported by the participating site.
Event-free rates were estimated with the use of the Kaplan–Meier method, with confidence 
intervals computed with the use of the log–log transformation and Greenwood’s variance. 
The data-cutoff date for the results presented here was July 29, 2015.
RESULTS
Characteristics of the Patients
Between April 7, 2006, and October 6, 2010, we enrolled 10,273 patients in the trial, of 
whom 10,253 were eligible to participate. A total of 1629 patients (1626 of whom were 
eligible [15.9% of the total eligible population]) had a recurrence score of 0 to 10 (indicating 
low risk), 6907 (6897 of whom were eligible [67.3% of the total eligible population]) had a 
score of 11 to 25 (indicating midrange risk), and 1736 (1730 of whom were eligible [16.9% 
of the total eligible population]) had a score of 26 or higher (indicating high risk). The 
median follow-up in the low-risk cohort was 69 months.
Table 1 shows the characteristics of the study population that was included in this analysis 
— patients with tumors associated with a recurrence score of 0 to 10 (low-risk cohort) — as 
compared with the characteristics of the patients who had a score of 11 to 25 (midrange-risk 
cohort). There were no significant differences in tumor size between these two cohorts. 
There was a similar distribution of intermediate-grade tumors (59% in the low-risk cohort 
and 57% in the midrange-risk cohort), although there was a significant difference in the 
distribution of grade, including low-grade tumors (34% vs. 29%) and high-grade tumors 
(7% vs. 14%) (P<0.001 for both comparisons). There were also significant but numerically 
modest differences between the low-risk cohort and the midrange-risk cohort with regard to 
age (median, 58 years vs. 55 years), menopausal status (postmenopausal status, 70% vs. 
64%), progesterone-receptor expression (progesterone-receptor–positive, 98% vs. 92%), and 
type of primary surgery (lumpectomy, 68% vs. 72%) (P<0.001 for all comparisons by the 
chisquare test).
Adjuvant Therapy
In the low-risk cohort of 1626 patients, endocrine therapy included an aromatase inhibitor in 
963 patients (59%), tamoxifen in 560 (34%), sequential tamoxifen followed by aromatase-
inhibitor therapy in 13 (1%), ovarian-function suppression in 44 (3%), or other or unknown 
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therapy in 46 (3%). Although the protocol specified that no chemotherapy be given if the 
recurrence score was 0 to 10, a total of 6 patients received adjuvant chemotherapy (1 of 
whom had a recurrence despite adjuvant chemotherapy).
Event Rates at 5 Years
In the cohort of patients with a recurrence score of 0 to 10, there were 88 events of either 
invasive cancer or death and 30 deaths reported within 5 years after study entry. The first 
event in the analysis of survival free from invasive disease was local or regional recurrence 
(or both) in 8 patients, distant recurrence in 10, invasive cancer of the opposite breast in 15, 
other invasive new primary cancer in 43, and death without another event in 12. The 
Kaplan–Meier estimates for each end point examined are shown in Figure 1.
In this cohort, the rate of invasive disease–free survival at 5 years was 93.8% (95% CI, 92.4 
to 94.9). The rate of freedom from recurrence of breast cancer at a distant site at 5 years was 
99.3% (95% CI, 98.7 to 99.6), the rate of freedom from recurrence at 5 years was 98.7% 
(95% CI, 97.9 to 99.2), and the rate of overall survival at 5 years was 98.0% (95% CI, 97.1 
to 98.6).
Multivariate Analysis and Effect of Tumor Grade and Age of the Patient
In a multivariate analysis that included age (≤50 years vs. 51 to 60 years vs. 61 to 75 years), 
tumor size (2.1 to 5.0 cm vs. ≤2 cm in the greatest dimension), histologic grade (high vs. 
intermediate vs. low), and surgery type (mastectomy vs. lumpectomy), only histologic grade 
showed a significant association with the rate of freedom from recurrence. However, 
histologic grade did not show a significant association with the rate of invasive disease–free 
survival or the rate of freedom from distant recurrence (Table 2). Recurrence rates were very 
low regardless of histologic grade (Table 3).
DISCUSSION
We performed a prospective validation study of a 21-gene assay in patients with hormone-
receptor–positive, HER2-negative breast cancer who had a low risk of recurrence according 
to clinicopathologic features but who nevertheless met established clinical guidelines for the 
recommendation or consideration of adjuvant chemotherapy. In patients who were found to 
have a low risk of recurrence on the basis of genetic-assay results and who were thus 
assigned to receive endocrine therapy alone, the risk of the recurrence of breast cancer at a 
distant site was less than 1% and the risk of any recurrence was less than 2% at 5 years.
Recurrence events were uncommon regardless of histologic grade and were not significantly 
affected by younger age at diagnosis. In fact, in this low-risk population, the rate of 
recurrence events at 5 years was far exceeded by the rates of second primary breast cancers, 
other second primary-cancer events, and deaths from other causes, which resulted in a rate 
of invasive disease– free survival that was nearly 5 percentage points lower than the rate of 
freedom from recurrence (93.8% vs. 98.7%).
Although adjuvant chemotherapy reduced the risk of distant recurrence and local–regional 
recurrence in the Early Breast Cancer Trialists meta-analysis, there was only a marginal 
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effect in reducing the risk of contralateral breast cancer and no effect on the risk of second 
primary cancers or on nonbreast-cancer mortality after 15 years of follow-up in nearly 
29,000 patients who had been randomly assigned to receive either chemotherapy or no 
chemotherapy.12 The low rate of distant recurrence observed in this prospective study is 
consistent with the rate observed at 5 years in the original prospective–retrospective 
validation study involving patients with a low recurrence score of less than 18 (2.1%; 95% 
CI, 0.6 to 3.7).14,15
The current prospectively conducted study supports the use of the 21-gene assay to spare the 
use of chemotherapy in patients who otherwise would be recommended to receive it on the 
basis of clinicopathologic features. These findings provide additional evidence supporting 
expert-derived clinical practice guidelines that recommend the use of this assay in patients 
with hormone-receptor– positive, axillary node–negative invasive breast cancer.21,24 
Although this study clearly identifies patients who do not benefit from adjuvant 
chemotherapy, only 16% of the enrolled patients had a recurrence score of 10 or less. 
Approximately 67% of the patients enrolled in the trial had a midrange score of 11 to 25 and 
were randomly assigned to receive chemotherapy plus endocrine therapy or endocrine 
therapy alone. Continued follow-up is required in order to determine the effect of 
chemotherapy in this larger group of patients.
Late recurrence that occurs after 5 years accounts for approximately one half of all distant 
recurrences in patients with estrogen-receptor–positive, HER2-negative breast cancer.25 
There are several prognostic gene-expression assays for breast cancer,26 some of which are 
more accurately prognostic for late recurrence than others.27,28 However, the 21-gene assay 
predicts benefit from adjuvant chemotherapy,16,17 and chemotherapy prevents primarily 
early recurrences within 5 years after diagnosis.8 Therefore, although more recurrences are 
expected with longer follow-up, it is unclear whether these recurrences would have been 
prevented by the early administration of adjuvant chemotherapy. Extended adjuvant 
endocrine therapy beyond 5 years is effective in preventing late recurrence and may be 
considered when the treating clinician and the patient perceive a favorable benefit–risk 
ratio.29,30
The distribution of recurrence scores observed in this prospective trial differs from the 
distribution that was initially projected on the basis of observations in a prior prospective–
retrospective validation study, which included 27% of patients with a score of 0 to 10, 43% 
with a score of 11 to 25, and 30% with a score of 26 or higher.14,16 This finding may be due 
to clinicians selecting patients for this study in whom there was therapeutic equipoise 
regarding the benefit of chemotherapy, which is reflected by the large proportion of patients 
who had tumors of 1.1 to 2.0 cm in the greatest dimension or tumors of intermediate 
histologic grade. However, the distribution of scores that was observed in this trial is similar 
to the distribution observed by the commercial laboratory during the same time period in 
which the study was conducted (score of 0 to 10 in 18% of patients, score of 11 to 25 in 
62%, and score of ≥26 in 20%; Shak S, Genomic Health: personal communication). This 
finding indicates that the distribution of risk groups in the trial reflects clinical practice in 
the community and supports the generalizability of the study findings.
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The RASTER (Microarray Prognostics in Breast Cancer) study was a prospective validation 
study that evaluated a different multigene assay, the 70-gene signature, in 427 patients with 
axillary node–negative breast cancer.31 The 5-year rate of freedom from distant recurrence 
was 97.0% among patients with a low-risk signature on the 70-gene assay (51% of all 
patients) and 91.7% among those with a high-risk signature (49% of all patients).32 
Decisions regarding adjuvant systemic treatment were based on the Dutch Institute for 
Healthcare Improvement 2004 guidelines, the 70-gene signature, and doctors’ and patients’ 
preferences. Adjuvant chemotherapy was given to 169 patients (81%) with a high-risk 
signature and in 33 (15%) with a low-risk signature. The outcomes observed in the RASTER 
study may therefore have been attributable, at least in part, to chemotherapy administered in 
selected patients in the low-risk group.
The MINDACT (Microarray in Node Negative Disease May Avoid Chemotherapy) trial is a 
prospective trial in which patients were randomly assigned to receive chemotherapy or no 
chemotherapy on the basis of clinical criteria or the 70-gene signature; enrollment has been 
completed and follow-up is ongoing.33 Although the results of the MINDACT trial are 
likely to provide important information, gene-expression assays bring added value by 
providing complementary predictive information that is independent of and does not 
correlate with clinicopathologic features in selected patients for whom this information may 
be clinically useful.34,35 Other ongoing trials (RxPONDER36 and OPTIMA37) are 
evaluating whether adjuvant chemotherapy is beneficial in patients with hormone-receptor– 
positive, HER2-negative breast cancer with positive axillary lymph nodes and a recurrence 
score of 25 or less.
In conclusion, this prospective study involving uniformly treated patients with hormone-
receptor– positive, HER2-negative, axillary node–negative breast cancer supports the 
clinical validity of the 21-gene assay in identifying patients who may be safely spared 
adjuvant chemotherapy.
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Figure 1. Kaplan–Meier Estimates in the Analyses of Invasive Disease–free Survival, Freedom 
from Recurrence of Breast Cancer at a Distant Site, Freedom from Recurrence at Any Site, and 
Overall Survival
A total of 1626 patients with a recurrence score of 0 to 10 (on a scale from 0 to 100, with 
higher scores indicating a greater risk of recurrence) were included in the analyses. In the 
time-to-event analysis of invasive disease–free survival, Panel A shows the probability of 
freedom from the first event of recurrence of ipsilateral breast tumor, local recurrence, 
regional recurrence, distant recurrence, contralateral second primary invasive cancer, second 
primary nonbreast invasive cancer (excluding nonmelanoma skin cancer), or death without 
evidence of recurrence (which corresponds to the standardized definitions for efficacy end 
points [STEEP]23 definition of invasive disease–free survival). In the time-to-event analysis 
of freedom from the recurrence of breast cancer at a distant site, Panel B shows the 
probability of freedom from the first event of distant recurrence of breast cancer or death 
with distant recurrence, if death was the first manifestation of distant recurrence (which 
corresponds to the STEEP definition of distant recurrence–free interval). In the time-to-
event analysis of freedom from recurrence at any site, Panel C shows the probability of 
freedom from the first event of recurrence of breast cancer (ipsilateral breast cancer, local or 
regional recurrence, or distant recurrence) or the date of death with recurrence, if death was 
the first manifestation of recurrence (which corresponds to the STEEP definition of 
Sparano et al. Page 12
N Engl J Med. Author manuscript; available in PMC 2016 May 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
recurrence-free interval). Panel D shows the probability of overall survival in the time-to-
event analysis. In each panel, dashed lines indicate 95% confidence intervals and the insets 
show the same data on an enlarged y axis.
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Table 1
Characteristics of the Patients at Baseline, According to Recurrence-Score Cohort.*
Characteristic
Recurrence Score,
0–10
(N = 1626)
Recurrence Score,
11–25
(N = 6897) P Value
Percent of all enrolled patients 15.9 67.3 —
Age
  Median (interquartile range) — yr 58 (50–64) 55 (48–62) <0.001
  Mean — yr 57±9 55±9 <0.001
  Distribution — no. (%) <0.001
    ≤40 yr 58 (4) 319 (5)
    41–50 yr 372 (23) 1964 (28)
    51–60 yr 566 (35) 2503 (36)
    61–70 yr 519 (32) 1811 (26)
    >70 yr 111 (7) 300 (4)
Menopausal status — no./total no. (%) <0.001
  Postmenopausal 1143/1623 (70) 4396/6873 (64)
  Premenopausal 480/1623 (30) 2477/6873 (36)
Tumor size in the greatest dimension
  Median (interquartile range) — cm 1.5 (1.2–2.0) 1.5 (1.2–2.0) 0.31
  Mean — cm 1.74±0.77 1.71±0.79 0.23
  Distribution — no./total no. (%) 0.42
    <1.0 cm 128/1626 (8) 568/6883 (8)
    1.0–1.9 cm 993/1626 (61) 4270/6883 (62)
    2.0–2.9 cm 366/1626 (23) 1543/6883 (22)
    3.0–3.9 cm 104/1626 (6) 358/6883 (5)
    ≥4.0 cm 35/1626 (2) 144/6883 (2)
Histologic grade of tumor — no./total no. (%) <0.001
  Low 530/1578 (34) 1941/6665 (29)
  Intermediate 937/1578 (59) 3812/6665 (57)
  High 111/1578 (7) 912/6665 (14)
Estrogen-receptor expression — no./total no. (%) 0.28
  Negative 5/1626 (<1) 10/6885 (<1)
  Positive 1621/1626 (>99) 6875/6885 (>99)
Progesterone-receptor expression — no./total no. (%) <0.001
  Negative 28/1590 (2) 528/6752 (8)
  Positive 1562/1590 (98) 6224/6752 (92)
Primary surgery — no./total no. (%) <0.001
  Lumpectomy 1106/1626 (68) 4986/6885 (72)
  Mastectomy 520/1626 (32) 1899/6885 (28)
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*
Plus–minus values are means ±SD. Patients were assigned to a risk cohort on the basis of the recurrence score on the 21-gene assay. Scores range 
from 0 to 100, with higher scores indicating a greater risk of recurrence. Patients with a score of 0 to 10 were included in the low-risk cohort and 
were assigned to receive endocrine therapy alone. Patients with a score of 11 to 25 were included in the midrange-risk cohort and were randomly 
assigned to receive either chemotherapy plus endocrine therapy or endocrine therapy alone. (Patients with a score of ≥26 were assigned to receive 
chemotherapy plus endocrine therapy and were not included in this analysis.) Statistical comparisons were calculated with the use of the chi-square 
test for categorical variables and the Wilcoxon test and Student’s t-test for continuous variables. Tumor size in the greatest dimension, histologic 
grade of the tumor, and expression of estrogen receptor, progesterone receptor, and HER2 were determined locally and reported by the 
participating site. Percentages may not total 100 because of rounding.
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Table 2
Multivariate Analysis.*
End Point Hazard Ratio (95% CI) P Value
Recurrence, second primary breast cancer, second primary nonbreast invasive cancer, or death without 
recurrence of cancer
  Tumor grade 0.13
    Intermediate vs. low 1.56 (0.92–2.63)
    High vs. low 2.05 (0.92–4.55)
  Tumor size >2 cm vs. ≤2 cm 1.17 (0.71–1.92) 0.54
  Age 0.07
    51–60 yr vs. ≤50 yr 0.87 (0.46–1.64)
    61–75 yr vs. ≤50 yr 1.53 (0.87–2.70)
  Lumpectomy vs. mastectomy 0.63 (0.38–1.06) 0.07
Recurrence at a distant site
  Tumor grade of high or intermediate vs. low† 3.83 (0.48–30.69) 0.14
  Tumor size >2 cm vs. ≤2 cm 1.55 (0.38–6.31) 0.55
  Age 0.27
    51–60 yr vs. ≤50 yr 1.28 (0.12–4.22)
    61–75 yr vs. ≤50 yr 3.49 (0.42–29.16)
  Lumpectomy vs. mastectomy 0.57 (0.12–2.82) 0.47
Recurrence at any site
  Tumor grade 0.02
    Intermediate vs. low 8.07 (1.06–61.45)
    High vs. low 4.73 (0.29–76.42)
  Tumor size >2 vs. ≤2 cm 1.06 (0.33–3.33) 0.93
  Age 0.33
    51–60 yr vs. ≤50 yr 0.41 (0.10–1.73)
    61–75 yr vs. ≤50 yr 0.98 (0.32–3.02)
  Lumpectomy vs. mastectomy 0.93 (0.32–2.71) 0.89
*
Data from 1578 of 1626 patients with a recurrence score of 0 to 10 were included in these analyses. Data from 48 patients for whom the histologic 
grade of the tumor was not reported were excluded from these analyses.
†
Data from patients with a high tumor grade and those with an intermediate tumor grade were combined for the analysis of freedom from the 
recurrence of breast cancer at a distant site because of the small number of events.
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Table 3
Event Rates at 5 Years, According to Histologic Grade.*
Tumor Grade
Invasive Disease– free
Survival
(95% CI)
Freedom from
Distant Recurrence
(95% CI)
Freedom from
Any Recurrence
(95% CI)
Overall Survival
(95% CI)
All grades 93.8 (92.4–94.9) 99.3 (98.7–99.6) 98.7 (97.9–99.2) 98.0 (97.1–98.6)
Low grade 95.8 (93.5–97.3) 99.8 (98.3–100) 99.8 (98.3–100) 98.7 (97.0–99.4)
Intermediate grade 93.6 (91.7–95.1) 99.0 (98.0–99.5) 98.2 (97.0–99.0) 97.9 (96.8–98.7)
High grade 91.3 (83.9–95.4) 100 (NC–NC) 98.7 (91.1–99.8) 97.3 (91.9–99.1)
*
The analyses for all tumor grades included data from all 1626 patients who had a recurrence score of 0 to 10, including the 48 patients with the 
tumor grade not reported. A total of 530 patients were included in the analyses for low-grade tumor, 937 in the analyses for intermediate-grade 
tumor, and 111 in the analyses for high-grade tumor. In the time-to-event analysis of invasive disease–free survival (primary end point), the rate 
indicates freedom from the first event of recurrence of ipsilateral breast tumor, local recurrence, regional recurrence, distant recurrence, 
contralateral second primary invasive cancer, second primary nonbreast invasive cancer (excluding nonmelanoma skin cancer), or death without 
evidence of recurrence (which corresponds to the standardized definitions for efficacy end points [STEEP]23 definition of invasive disease–free 
survival). In the time-to-event analysis of recurrence of breast cancer at a distant site, the rate indicates freedom from the first event of distant 
recurrence of breast cancer or death with distant recurrence, if death was the first manifestation of distant recurrence (which corresponds to the 
STEEP distant recurrence–free interval definition). In the time-to-event analysis of freedom from any recurrence, the rate indicates freedom from 
the first recurrence of breast cancer (ipsilateral breast cancer, local or regional recurrence, or distant recurrence) or the date of death with 
recurrence, if death was the first manifestation of recurrence (which corresponds to the STEEP recurrence-free interval definition). NC denotes not 
calculated.
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